International Journal of Advanced and Integrated Medical Sciences

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  3 (2018)
Volume  2 (2017)
Volume  1 (2016)
Related articles

VOLUME 2 , ISSUE 4 ( 2017 ) > List of Articles

ORIGINAL ARTICLE

Dyslipidemia in Women with Polycystic Ovary Syndrome in Khammam District, Telangana, India

Malidu Priyanka, Madrol V Bhaskar, Manchikanti Madhulatha, Praveen K Kodumuri

Keywords : Cardiovascular disease, Dyslipidemia, Non-high-density lipoprotein cholesterol, Polycystic ovary syndrome

Citation Information : Priyanka M, Bhaskar MV, Madhulatha M, Kodumuri PK. Dyslipidemia in Women with Polycystic Ovary Syndrome in Khammam District, Telangana, India. Int J Adv Integ Med Sci 2017; 2 (4):183-187.

DOI: 10.5005/jp-journals-10050-10102

License: CC BY-SA 4.0

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract

Introduction Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders of women in the reproductive age group, with a prevalence of 5 to 10% of the female population. Dyslipidemia, insulin resistance, and obesity are all potent cardiovascular risk factors that tend to cluster in women with PCOS. The Androgen Excess-PCOS Society consensus statement recommended a complete lipid profile, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), non-HDL-cholesterol (non-HDL-C), and triglycerides (TGs) in all subjects with PCOS for cardiovascular risk prevention. Aim The purpose of this study is to evaluate lipid levels in subjects with PCOS and to correlate with obesity. Materials and methods Study group comprised 142 women with PCOS and 65 healthy non-PCOS subjects. Body mass index (BMI), waist circumference, and lipids were measured in PCOS subjects and age-matched non-PCOS subjects. Statistical analysis All values are expressed as mean ± standard deviation (SD). The results obtained are analyzed statistically using unpaired t-test to evaluate the significance of difference between the mean values. Results The mean BMI, waist circumference, serum cholesterol, TGs, LDL-C, and non-HDL-C values significantly increased, whereas serum HDL-C significantly decreased in PCOS subjects when compared with non-PCOS subjects, and serum lipids correlated with obesity. Conclusion Dyslipidemia was observed in the present study and serum lipid levels correlated with obesity in women with PCOS. How to cite this article Priyanka M, Bhaskar MV, Madhulatha M, Kodumuri PK. Dyslipidemia in Women with Polycystic Ovary Syndrome in Khammam District, Telangana, India. Int J Adv Integ Med Sci 2017;2(4):183-187.

PDF Share
  1. Li L, Yang D, Chen X, Chen Y, Feng S, Wang L. Clinical and metabolic features of polycystic ovary syndrome. Int J Gynecol Obstet 2007 May;97(2):129-134.
  2. The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004 Jan;19(1):41-47.
  3. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007 Aug;370(9588):685-697.
  4. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010 May;95(5):2038-2049.
  5. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001 Dec;111(8):607-613.
  6. Bahceci M, Aydemir M, Tuzcu A. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 2007 Jun;87(6):1363-1368.
  7. Sukalich S, Guzick D. Cardiovascular health in women with polycystic ovary syndrome. Semin Reprod Med 2003 Aug;21(3):309-316.
  8. Hoffman LK, Ehrmann DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2008 Apr;4(4):215-222.
  9. Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E, Koutsilieris M. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome. J Steroid Biochem Mol Biol 2008 Apr;109(3-5):242-246.
  10. Grundy SM, Cleeman JL, Mercz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 Jul;110(2):227-239.
  11. Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA, National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol 2008 Aug;2(4):267-273.
  12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of the national cholesterol education program (NCEP) Expert panel on Detection, Evaluation and Treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001 May;285(19):2486-2497.
  13. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011 Mar;95(3):1073-1079. e1-e11.
  14. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995 Jul;15(7):821-826.
  15. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001 Apr;54(4):447-453.
  16. Karabulut AB, Cakmak M, Kiran RT, Sahin I. Oxidative stress status, metabolic profile and cardiovascular risk factors in patients with polycystic ovary syndrome. Med Sci 2012 Jan;1(1):27-34.
  17. Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW, Welborn TA, AusDiab Steering Committee. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med 2003 Dec;254(6):555-563.
  18. Chan DC, Watts GF. LDL heterogeneity revisited: lesson for the metabolic syndrome from a new interpopulation study? Eur J Clin Invest 2004 Nov;34(11):719-722.
  19. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos P. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007 Sep;18(7):280-285.
  20. Brunzell JD, Davidson M, Furberg CD. Lipoprotein management in patients with cardio metabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008 Apr;51(4):1512-1524.
  21. Nordestgaard BG, Langsted A, Freiberg JJ. Nonfasting hyperlipidemia and cardiovascular disease. Curr Drug Targets 2009 Apr;10(4):54-61.
  22. Peters AL. Clinical relevance of non-HDL cholesterol in patients with diabetes. Clin Diabetes 2008 Jan;26(1):3-7.
  23. Vaughan N, James K, McDermott D, Griest S, Fausti S. A 5-year prospective study of diabetes and hearing loss in a veteran population. Otol Neurotol 2006 Jan;27(1):37-43.
  24. Tosi A, Misciali C, Piraccini B, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994 Apr;10(4):310-317.
  25. Bronner AK, Hood AF. Cutaneous complication of chemotherapeutic agents. J Am Acad Dermatol 1983 Nov;9(5):645-663.
  26. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am 1986 Jan;70(1):187-209.
  27. Boyle DM, Engelking C. Vesicant extravasation: myths and realities. Oncol Nurs Forum 1995 Jan-Feb;22(1):57-67.
  28. Malkinson, FD. Radiobiology of the skin. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick's dermatology in general medicine. 5th edn. New York: McGraw-Hill; 1999. pp. 1514-1523.
  29. Goldschmidt H, Breneman JC, Bareneman DL. Ionizing radiation therapy in dermatology. J Am Acad Dermatol 1994 Feb;30(2 Pt 1):157-182.
  30. Narkiewicz K, van de Borne P, Montano N, Hering D, Kara T, Somers VK. Sympathetic neural outflow and chemoreflex sensitivity are related to spontaneous breathing rate in normal men. Hypertension 2006;47(1):51-55.
  31. Agte VV, Chiplonkar SA. Sudarshan kriya yoga for improving antioxidant status and reducing anxiety in adults. Altern Complement Ther 2008;14(2):96-100.
  32. Jacobs GD. Clinical applications of the relaxation response and mind-body interventions. J Altern Complement Med 2001;7(Suppl 1):S93-S101.
  33. Singh N, Telles S. Heart rate variability and state anxiety in hypertensives and diabetes after one week of yoga. J Indian Psychol 2009;27(1-2):13-20.
  34. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. J Hum Hypertens 2004 Mar;18(3):139-185.
  35. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011 Jul-Aug;27(4):415-433.e1-2.
  36. Wahlgren NG, MacMahon DG, De Keyser JF, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994 May;4(3):204-10.
  37. Kaste M, Fogelholm R, Erilä T, Palomäki H, Murros K, Rissanen A, Sarna S. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994 Jul;25(7):1348-1353.
  38. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003 Jul;34(7):1699-1703.
  39. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011 Feb;377(9767):741-750.
  40. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009 Jan;8(1):48-56.
  41. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010 Aug;9(8):767-775.
  42. Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke 2013 Mar;44(3):870-947.
  43. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Stroke 2009 Jul;40(7):2442-2449.
  44. Karachalios GN, Charalabopoulos A, Papalimneou V, Kiortsis D, Dimicco P, Kostoula OK, Charalabopoulos K. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract 2005 May;59(5):562-570.
  45. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-1041.
  46. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke 2005 Jun;36(6):1218-1226.
  47. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008 Sep;359(12):1225-1237.
  48. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2014 Jan:45(7):2160-2236.
  49. Robb AO, Mills NL, Din JN, Smith IB, Paterson F, Newby DE, Denison FC. Influence of the menstrual cycle, pregnancy, and preeclampsia on arterial stiffness. Hypertension 2009 Jun;53(6):952-958.
  50. Avni B, Frenkel G, Shahar L, Golik A, Sherman D, Dishy V. Aortic stiffness in normal and hypertensive pregnancy. Blood Press 2010 Feb;19(1):11-15.
  51. Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH. Maternal hemodynamics at 11–13 weeks’ gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol 2012 Jul;40(1):28-34.
  52. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992 Feb;304(6824):405-412.
  53. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar;359(9311):995-1003.
  54. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trials-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep;366(9489):895-906.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.